The Filing Desk

ProQR Therapeutics

PRQR · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

PRQR · Last close · November 19, 2026
$1.05

ProQR Therapeutics' revenue fell 15.9% to €16 million in fiscal 2025. Its operating margin was −273.1%, down from −161.2% a year earlier. Free cash flow was −€54 million. The diluted share count rose 22.4%.

ProQR Therapeutics N.V. Latest fiscal year ended December 31, 2025 20-F filed March 12, 2026 · 0001104659-26-026713 Updated
Revenue
€16M
15.9%
Operating margin
−273.1%
112.0 pts
Net income
−€42M
 
Free cash flow
−€54M
 
Return on equity
−61.2%
18.4 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.

About these figures. ProQR Therapeutics is a foreign company: it files an annual report on Form 20-F, prepared under international accounting standards (IFRS), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model. Its figures are in EUR, as it reports them: they aren't converted to US dollars.

Income statement

Revenue and net income
EUR billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
EUR billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

ProQR Therapeutics lost money in fiscal 2025: a net loss of €42 million.

Diluted earnings per share
EUR per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
EUR billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
EUR billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1889511914992
Debt incl. finance leases49————
Net debt (negative means net cash)−139————
Net debt to EBITDA—————
Debt to equity0.4x————
Interest coverage−16.8x−12.7x−26.5x−28.3x−46.8x
Current ratio6.9x7.4x3.5x4.0x3.1x
Quick ratio6.9x7.4x3.5x4.0x3.1x
EUR millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
EUR billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
EUR billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
EUR billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40391.0%−9.8%−354.2%
Altman Z''−6.45−3.85−11.35
Accruals ratio−32.1%5.6%7.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assets———
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassFail
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put ProQR Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
ProQR TherapeuticsFY25−15.9%−273.1%−338.3%———
Opus GeneticsFY2529.1%−271.9%———3Compare
Pyxis OncologyFY25−14.2%−609.2%−458.3%———Compare
Tonix PharmaceuticalsFY2529.9%−959.0%−787.5%———Compare
Sol-Gel TechnologiesFY2568.0%−38.9%1.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—————1461916
Revenue growth——————169.2%81.2%190.2%−15.9%
Gross profit——————————
Research and development32313046384251253645
Operating income−40−40−36−57−42−57−65−32−30−43
Net income−39−44−37−56−47−61−64−28−28−42
Diluted EPS (EUR)−1.67−1.72−1.08−1.38−0.93−0.95−0.90−0.35−0.32−0.40
Diluted shares (millions)232534415064728186105
Cash flow
Cash from operations−34−35−28−44−47−26−6822−36−53
Capital expenditure2001101111
Free cash flow−37−35−29−45−48−26−6920−38−54
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation2459863324
Balance sheet at fiscal year end
Cash and short-term investments5948106112761889511914992
Debt incl. finance leases67—131749————
Total assets665311011899210171138168113
Total liabilities121418244296105967963
Shareholders' equity533993945711467418949
Margins and ratios
Gross margin——————————
Operating margin—————−4,285.4%−1,813.0%−489.1%−161.2%−273.1%
Net margin—————−4,549.8%−1,792.5%−431.7%−146.9%−265.2%
Free cash flow margin—————−1,984.7%−1,925.9%309.8%−200.0%−338.3%
Rule of 40 (growth + FCF margin)——————−1,756.7%391.0%−9.8%−354.2%
Return on capital——————————
Return on equity—−94.3%−55.8%−60.3%−61.5%−71.1%−71.2%−51.9%−42.7%−61.2%
Return on assets—−73.6%−45.2%−49.6%−43.1%−39.4%−33.8%−18.2%−18.2%−30.1%
Net debt to EBITDA——————————
EUR millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, EUR millions)
Source: ProQR Therapeutics' Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with ProQR Therapeutics.